REMS
Absorption: Bioavailability of oral formulations is 7080%. Extended-release preparations are absorbed slowly following oral administration.
Distribution: Widely distributed. Cross the placenta; enter breast milk.
Half-Life: 68 hr (↑ in HF or severe liver impairment).
(antiarrhythmic effects)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO (sulfate) | 30 min | 11.5 hr | 68 hr |
PO (sulfate-ER) | unknown | 4 hr | 812 hr |
PO (gluconate) | unknown | 34 hr | 68 hr |
Contraindicated in:
Use Cautiously in:
CV: arrhythmias, HYPOTENSION, palpitations, tachycardia, TORSADES DE POINTES
Derm: rash
EENT: blurred vision, diplopia, mydriasis, photophobia, tinnitus
GI: abdominal cramping, anorexia, diarrhea, nausea, vomiting, drug-induced hepatitis
Hemat: AGRANULOCYTOSIS, hemolytic anemia, thrombocytopenia
Neuro: dizziness, ataxia, confusion, fatigue, headache, syncope, tremor, vertigo
Misc: fever
Drug-drug:
Quinidine Gluconate
Quinidine Sulfate
Lab Test Considerations:
Toxicity and Overdose:
IV Administration: